NMS after clozapine initiation [2]

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 44, Issue 11, 2005, Pages 1101-1102

  Skarpathiotakis, Mia ^a   Westreich, Neal ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; CREATINE KINASE; FLUPHENAZINE; LOXAPINE; OLANZAPINE; OXCARBAZEPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ANTICHOLINERGIC EFFECT; AUTISM; CASE REPORT; DYSTONIA; HUMAN; HYPERTENSION; LETTER; MALE; MENTAL HEALTH; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 27144489648     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.chi.0000177328.92333.2b     Document Type: Letter

References (3)

1. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T (2004), Neuroleptic malignancy syndrome and atypical antipsychotic drugs. J Clin Psychiatry 65:464-470
2. Ciapparelli A, Dell'Osso L, Bandettini di Poggio A, Carmassi C, Cecconi D, Fenzi M, et al. (2003), Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry 64:451-458
3. Naber D, Hippius H (1990), The European experience with use of clozapine. Hosp Community Psychiatry 41:886-890